<--- Back to Details
First PageDocument Content
Amyotrophic lateral sclerosis / ALS Therapy Development Institute / Medicine / Chemistry / SOD1 / Riluzole / Augie Nieto / Minocycline / Creatine / Health / Rare diseases / Motor neurone disease
Date: 2008-02-05 13:21:33
Amyotrophic lateral sclerosis
ALS Therapy Development Institute
Medicine
Chemistry
SOD1
Riluzole
Augie Nieto
Minocycline
Creatine
Health
Rare diseases
Motor neurone disease

Media Contacts Sean A. Scott, President ALS Therapy Development Institute[removed]removed] Charles Versaggi, Ph.D.

Add to Reading List

Source URL: www.als.net

Download Document from Source Website

File Size: 109,03 KB

Share Document on Facebook

Similar Documents

Amyotrophic lateral sclerosis (ALS) is a chronic relentless neurodegenerative disorder and it is the most common motor neuron disorder of the adult life

Amyotrophic lateral sclerosis (ALS) is a chronic relentless neurodegenerative disorder and it is the most common motor neuron disorder of the adult life

DocID: 1sGJy - View Document

New NIH guidelines to improve Experimental Rigor and Reproducibility Oswald Steward Professor, Department of Anatomy & Neurobiology Senior Associate Dean for Research University of California School of Medicine

New NIH guidelines to improve Experimental Rigor and Reproducibility Oswald Steward Professor, Department of Anatomy & Neurobiology Senior Associate Dean for Research University of California School of Medicine

DocID: 1rjyT - View Document

...................................  OCCUPATIONAL Therapy Overcome your limitations.

................................... OCCUPATIONAL Therapy Overcome your limitations.

DocID: 1qQof - View Document

Caffeic acid phenethyl ester extends survival of a mouse model of amyotrophic lateral sclerosis

Caffeic acid phenethyl ester extends survival of a mouse model of amyotrophic lateral sclerosis

DocID: 1qMIa - View Document

Sarah Ayer 311 Thornton Drive Franklin, TX0000 January 31, 1999 David McMurrey

Sarah Ayer 311 Thornton Drive Franklin, TX0000 January 31, 1999 David McMurrey

DocID: 1qFos - View Document